Citigroup
BNTC icon

Citigroup’s Benitec Biopharma BNTC Stock Holding History

Citigroup’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.31K Buy
874
+330
+61% +$3.82K ﹤0.01% 5068
2025
Q4 		$7.33K Sell
544
-92
-14% -$1.27K ﹤0.01% 5145
2025
Q3 		$8.92K Sell
636
-4,503
-88% -$57.5K ﹤0.01% 5058
2025
Q2 		$60.1K Sell
5,139
-1,016
-17% -$14.2K ﹤0.01% 4663
2025
Q1 		$80.1K Sell
6,155
-6,308
-51% -$76.3K ﹤0.01% 4711
2024
Q4 		$157K Buy
+12,463
New +$135K ﹤0.01% 4566
2022
Q3 		– Sell
-202
Closed -$4K – 5845
2022
Q2 		$4K Buy
202
+201
+20,100% +$4.67K ﹤0.01% 5663
2022
Q1 		$0 Buy
+1
New +$41 ﹤0.01% 6313

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citigroup's BNTC Position: Q1 2026 in Review

Citigroup increased its Benitec Biopharma (BNTC) stake by 61% in Q1 2026, buying an estimated $3.82K and bringing the position to 874 shares worth $9.31K. The position accounts for ﹤0.01% of the portfolio, ranked #5068.

Citigroup first reported a position in BNTC in Q1 2022 and has held it in 8 quarters since. The position peaked at $157K in Q4 2024. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Citigroup held 874 shares of Benitec Biopharma worth $9.31K as of Q1 2026.
  • Citigroup bought 330 Benitec Biopharma shares in Q1 2026, an estimated $3.82K.
  • Benitec Biopharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5068 holding.
  • Citigroup first reported a position in Benitec Biopharma in Q1 2022 and has held it in 8 quarters since.
  • Citigroup's Benitec Biopharma position peaked at $157K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.